Document Detail


The alpha1-adrenergic blocker urapidil improves contractile function in patients 3 months after coronary stenting: a randomized, double-blinded study.
MedLine Citation:
PMID:  14760340     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The recovery of left ventricular function (LVF) after revascularization takes time. alpha-Adrenergic blockade acutely improves coronary blood flow and LVF, whereas the effects of more prolonged alpha-adrenergic blockade on LVF recovery after stenting are unknown. METHODS: In 32 patients (age 58 +/- 12 y) with an 82% +/- 6% stenosis, ejection fraction (EF) and systolic thickening (%Th) were measured by transthoracic echocardiography before and 30 minutes to 2 hours after revascularization. In a double-blinded protocol, either 200 microg/kg urapidil or placebo was given intravenously, and LVF was measured 10 minutes later. Two hours later, oral treatment with 30 mg/d drug or placebo was started, and LVF measured again after 24 hours and 3 months. RESULTS: Before revascularization, EF was 49.4% +/- 8.5% (+/-SD) and 51.3% +/- 8.8% in the urapidil-treated and the placebo groups, respectively. Thirty minutes to 2 hours after coronary stenting, EF was unchanged. After intravenous drug administration, EF increased to 56.5% +/- 9.7%). At 24 hours and 3 months after revascularization, EF became 59.5% +/- 7.9% and 59.6% +/- 8.2% in the urapidil-treated group, respectively, whereas EF in the placebo group did not change (50.4% +/- 5.7% and 49.7% +/- 4.9%, respectively). Revascularization did not acutely improve %Th. Intravenous urapidil improved %Th from 31.4% +/- 17.6% to 44.2% +/- 11.6%, whereas there was no change in the placebo group. At 3 months, %Th was 49.5% +/- 12.9% in the urapidil-treated group and 39.7% +/- 8.9% in the placebo group. CONCLUSIONS: These data suggest that long-term alpha-adrenergic blockade might improve LVF at midterm after coronary revascularization.
Authors:
Michaela Kozàkovà; Jean Marco; Gerd Heusch; Monique Bernies; Irene M Bossi; Carlo Palombo; Gian Battista Anguissola; Francesco Donatelli; Jean Pierre Laurent; Luisa Gregorini
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American heart journal     Volume:  147     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-02-04     Completed Date:  2004-03-26     Revised Date:  2006-02-27    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E6     Citation Subset:  AIM; IM    
Affiliation:
Clinique Pasteur, Centre de Cardiologie Interventionelle, Toulouse, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / pharmacology,  therapeutic use*
Adult
Aged
Angina Pectoris / drug therapy,  physiopathology,  therapy*
Angioplasty, Transluminal, Percutaneous Coronary
Double-Blind Method
Female
Humans
Male
Middle Aged
Myocardial Contraction / drug effects
Piperazines / pharmacology,  therapeutic use*
Stents*
Stroke Volume / drug effects*
Ventricular Dysfunction, Left / drug therapy
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Piperazines; 34661-75-1/urapidil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Red wine's antioxidants counteract acute endothelial dysfunction caused by cigarette smoking in heal...
Next Document:  Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis aft...